Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are MetGlobeNewsWire · 4 days ago
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade IbogaineGlobeNewsWire · Oct 5, 2026
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research CorporationGlobeNewsWire · Sep 28, 2026
Psyence BioMed Announces Strategic Ibogaine InvestmentGlobeNewsWire · Sep 23, 2026
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine DevelopmentGlobeNewsWire · Sep 14, 2026
Modular Medical Secures National PBM Contract For Pivot Insulin PumpBenzinga · Sep 4, 2026Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study.